Evaxion A/S has announced plans to expand its proprietary AI-Immunology™ platform to target autoimmune diseases, adding this as a third therapeutic area alongside cancer and infectious diseases. The company aims to apply and train its AI-Immunology™ technology for autoimmune disease applications in the second half of 2026, with the intention of developing precision treatments that address underlying disease mechanisms. Additional company milestones for 2026 include generating new biomarker and immunogenicity data for EVX-01 in the first half of the year, obtaining three-year phase 2 clinical efficacy data for EVX-01, filing for a phase 1 trial of EVX-04, and completing design and preclinical validation of antigens for EVX-B4 in the second half of the year. The expansion and related development activities are accounted for in the company’s financial outlook, with the cash runway projected to extend into the second half of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001159041-en) on January 13, 2026, and is solely responsible for the information contained therein.
